Development and Evaluation of Hydrophilic Colloid Matrix of Famotidine Tablets
The objective of the present study was to develop a once-daily sustained-release (SR) matrix tablet of famotidine. Nine different formulations (F1–F9) were prepared by direct compression method using Avicel PH101 as filler/binder in the range of 41–27% in F1–F3, 18–22% in F4–F7, and 16–18% in F8–F9 and hydroxypropyl methylcellulose (4,000 cps) as hydrophilic matrix was used in F1–F3 from 19% to 30%, around 40% in F4–F7, and 42–45% in F8–F9. Talc and Aerosil were added in the ratio of 0.7–1.2%. The tablets were subjected to various physical parameters including weight variation test, hardness, thickness, diameter, friability, and in vitro release studies. Assay was also performed according to the USP 30 NF 25 procedure. The results of the physical parameters and assay were found to be within the acceptable range. In vitro dissolution results indicated that formulation F4–F7, having around 40% of rate control polymer, produced a SR pattern throughout 24 h. F1–F3 showed drug release at a faster rate, while F8–F9 released much slower, i.e., <80% in 24 h. Model-dependent and model-independent methods were used for data analysis and the best results were observed for F4 in zero order (r 2 = 0.984) and F6 in Korsmeyer and Higuchi (r 2 = 0.992 and 0.988). The parameter n indicated anomalous diffusion, while β in Weibull showed a parabolic curve with higher initial slope. The f 2 similarity test was performed taking F4 as a reference formulation. Only the F5–F7 formulations were similar to the reference formulation F4. The mean dissolution time was around 10 h for the successful formulation.
Key wordsfamotidine hydrophilic colloid matrix hydroxypropyl methylcellulose (HPMC) kinetics sustained release
- 1.Dollery C. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999.Google Scholar
- 2.Pepsid. Electronic medicines compendium. Aventis Pharma Ltd. http://emc.medicines.org.uk/emc/assets/c/html/display.doc. Accessed 01 Aug 2003.
- 3.Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int J Pharm Technol Prod Manuf. 1984;5:1–9.Google Scholar
- 4.Reza MS, Quadir MA, Haid SS. Comparative evaluation of plastic hydrophobic and hydrophilic polymers as matrices for controlled release drug delivery. J Pharm Pharm Sci. 2003;6(2):274–91.Google Scholar
- 5.Gothoskar AV. Study of effect of polymer viscosity and polymer: excipient ratio on drug-release patterns from swellable matrices. Drug Delivery Technology. 2005;5:1–7.Google Scholar
- 6.VIVAPHARM, cellulose-based polymer for film-coating and sustained-release application. http://www.jrspharma.de/. Accessed 01 Aug 2005.
- 7.Rawlins EA. Bentley’s textbook of pharmaceutics. 8th ed. UK: Baillieve Tindall; 1986.Google Scholar
- 8.British pharmacopoeia. London: Stationary Office London; 2004.Google Scholar
- 9.Gad SC. Pharmaceutical manufacturing handbook. New York: Wiley; 2008.Google Scholar
- 10.United States pharmacopoeia 23. Rockville: US Pharmacopeial Convention; 1995.Google Scholar
- 11.Hanson WA. Handbook of dissolution testing: compendial method. USA: Pharmaceutical Technology Publication; 1982.Google Scholar
- 12.Hadjiioannou TP, Christian GD, Koupparis MA, Macheras PE. Quantitative calculations in pharmaceutical practice and research. New York: VCH; 1993.Google Scholar
- 13.Bourne DW. Pharmacokinetics. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics. 4th ed. New York: Marcel Dekker; 2002. p. 66–91.Google Scholar
- 19.Baker RW, Lonsdale HS. Controlled release: mechanism and rates. Controlled release of biologically active agents. New York: Plenum; 1974. p. 15–71.Google Scholar
- 21.Tiwari SB, Rajabi-Siahboomi AR. Applications of complementary polymers in HPMC hydrophilic extended release matrices. Drug Deliv Tech. 2009;9(7):20–7.Google Scholar
- 24.Dow Excipients. Technical presentations. http://www.dow.com/dowexcipients/resources/product/methocel/meth_presentations.htm (2009). Accessed 31 May 2009.
- 26.Bravo SA, Lamas MA, Salomon CJ. In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices. J Pharm Sci. 2002;5(3):213–9.Google Scholar
- 29.Hakim M. Evaluation of a new rate retarding polymer Kollidon SR as matrix tablets. M.Pharm. thesis, Bangladesh, DU; 2001.Google Scholar
- 30.Patel N, Chotai N, Patel J, Soni T, Desai J, Patel R. Comparison of in-vitro dissolution profiles of oxcarbazepine-HP β-CD tablet formulations with marketed oxcarbazepine tablets. http://www.dissolutiontech.com (2008). Accessed 18 Jan 2009.
- 31.Karmakar AB, Gonjari ID, Hosmani AH, Dhabale PN, Bhise SB. Dissolution rate enhancement of fenofibrate using liquisolid tablet technique. Part II: evaluation of in vitro dissolution profile comparison method. Lat Am J Pharm. 2009;28(2):219–25.Google Scholar
- 32.Yuksel N, Kanik AE, Baykara T. Comparison of in vitro dissolution profiles by ANOVA based model dependent and independent methods. Int J Pharm. 2009;209:56–67.Google Scholar